AEMD Nasdaq

Aethlon Medical, Inc.

AEMD 4 | $1.5119 1.33% 620

(0.0% 1d) (-12.6% 1m) (287.6% 1y) (0.0% 2d) (1.3% 3d) (4.8% 7d) (-96.37% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 3,961,781
http://www.aethlonmedical.com
Sec Filling | Patents | 8 employees

(US) Aethlon Medical, Inc. is a therapeutic technology company, which focuses on addressing global health and biodefense needs. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The firm operates through two segments: Aethlon and ESI. The Aethlon segment involves in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.

cancer diagnostics hemopurifier blood filtration

add to watch list Paper trade email alert is off

Press-releases

Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
Published: 2024-02-21 (Crawled : 13:00) - prnewswire.com
AEMD 4 | $1.5119 1.33% 620

Health Technology

| -7.27% | O: 0.0% H: 8.45% C: 3.03%
transfer medical agreement

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024
Published: 2024-02-07 (Crawled : 14:30) - biospace.com/
AEMD 4 | $1.5119 1.33% 620

Health Technology

| -14.04% | O: -2.81% H: 2.21% C: 2.21%
conference medical financial results

Exosome Research Market Worth $356 Million | MarketsandMarkets™
Published: 2024-01-17 (Crawled : 15:30) - prnewswire.com
DHR | $250.41 -1.07% -0.72% 3.3M

Health Technology

| 10.43% | O: -0.53% H: 1.6% C: -0.43%
IESC | News | $128.73 0.85% 0.84% 190K

Industrial Services

| 62.16% | O: -1.06% H: 3.2% C: 2.44%
AEMD 4 | $1.5119 1.33% 620

Health Technology

| -21.13% | O: -3.09% H: 1.06% C: 0.53%
million research market

Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer
Published: 2023-11-13 (Crawled : 13:00) - prnewswire.com
AEMD 4 | $1.5119 1.33% 620

Health Technology

| -11.05% | O: 0.0% H: 9.88% C: -4.07%
medical

Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023
Published: 2023-11-06 (Crawled : 13:00) - prnewswire.com
AEMD 4 | $1.5119 1.33% 620

Health Technology

| -18.18% | O: -1.07% H: 4.32% C: 3.24%
conference medical financial results

Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology
Published: 2023-10-10 (Crawled : 12:00) - prnewswire.com
AEMD 4 | $1.5119 1.33% 620

Health Technology

| -14.53% | O: -2.23% H: 14.86% C: -1.71%
hemopurifier drug india clearance trial potential

Aethlon Announces Reverse Stock Split
Published: 2023-10-04 (Crawled : 12:00) - prnewswire.com
AEMD 4 | $1.5119 1.33% 620

Health Technology

| -30.45% | O: -5.91% H: 10.63% C: -5.27%

Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Published: 2023-08-30 (Crawled : 12:00) - prnewswire.com
AEMD 4 | $1.5119 1.33% 620

Health Technology

| -47.06% | O: 0.69% H: 0.0% C: -4.81%
conference global medical

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 10, 2023
Published: 2023-08-03 (Crawled : 12:00) - prnewswire.com
AEMD 4 | $1.5119 1.33% 620

Health Technology

| 346.85% | O: 1.58% H: 4.97% C: -1.47%
conference medical financial results

Aethlon Medical Signs Collaboration Agreement with 34 Lives to Evaluate the Ability of the Hemopurifier® to Expand the Utility of Unused, Donated Kidneys for Transplant
Published: 2023-07-24 (Crawled : 12:00) - prnewswire.com
AEMD 4 | $1.5119 1.33% 620

Health Technology

| 318.03% | O: 8.47% H: 0.0% C: -6.65%
hemopurifier collaboration medical agreement

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001415889-24-011030	4	2024-04-17	2024-04-16	Buy	A	32894	200543
0001415889-24-011028	4	2024-04-17	2024-04-16	Buy	A	32894	44532
0001415889-24-011025	4	2024-04-17	2024-04-16	Buy	A	32894	46574
0001209191-24-000226	4	2024-01-02	2023-12-29	Sell	F	1954	15634